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Deregulation of the cyclin-dependent kinases (CDKs) has been implicated
in the pathogenesis of multiple cancer types. Consequently, CDKs have
garnered intense interest as therapeutic targets for the treatment of cancer.
We describe herein the molecular and cellular effects of CCT068127, a
novel inhibitor of CDK2 and CDK9. Optimized from the purine template
of seliciclib, CCT068127 exhibits greater potency and selectivity against
purified CDK2 and CDK9 and superior antiproliferative activity against
human colon cancer and melanoma cell lines. X-ray crystallography studies
reveal that hydrogen bonding with the DFG motif of CDK2 is the likely
mechanism of greater enzymatic potency. Commensurate with inhibition of
CDK activity, CCT068127 treatment results in decreased retinoblastoma
protein (RB) phosphorylation, reduced phosphorylation of RNA
polymerase II, and induction of cell cycle arrest and apoptosis. The tran-
scriptional signature of CCT068127 shows greatest similarity to other
small-molecule CDK and also HDAC inhibitors. CCT068127 caused a dra-
matic loss in expression of DUSP6 phosphatase, alongside elevated ERK
phosphorylation and activation of MAPK pathway target genes. MCL1
protein levels are rapidly decreased by CCT068127 treatment and this asso-
ciates with synergistic antiproliferative activity after combined treatment
with CCT068127 and ABT263, a BCL2 family inhibitor. These findings
support the rational combination of this series of CDK2/9 inhibitors and
BCL2 family inhibitors for the treatment of human cancer.
Abbreviations
BrdU, bromodeoxyuridine; CDK, cyclin-dependent kinase inhibitor; CDKI, cyclin-dependent kinase inhibitor; CI, combination index; GI50, 50%
growth inhibition; HDAC, histone deacetylase; IAP, inhibitor of apoptosis; MAPK, mitogen-activated protein kinase; RT-qPCR, real-time
quantitative polymerase chain reaction; SDS/PAGE, sodium dodecyl sulfate/polyacrylamide gel electrophoresis; siRNA, short interfering
ribonucleic acid.
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1. Introduction
Loss of cell cycle control is a hallmark of human can-
cer, and this can be achieved by overexpression of the
CDK partner cyclins or by decreased expression or
mutation of CDK inhibitors (CDKIs) from the INK4
and CIP/KIP families (Malumbres and Barbacid,
2009). For example, amplification of the 19q12 locus
has been reported in up to 15% of estrogen receptor
(ER)-negative breast cancers, typically resulting in
amplification of CCNE1 (cyclin E1) (Adela€ıde et al.,
2007; Natrajan et al., 2012). The G1-to-S-phase transi-
tion is regulated by CDK4/cyclin D and CDK6/cyclin
D. CDK2/cyclin A, CDK2/cyclin E, and CDK1/cyclin
A mediate progression through S phase to G2 and
CDK1/cyclin B activity is involved in the initiation of
mitosis (Malumbres and Barbacid, 2009). Importantly,
CDK activities converge to phosphorylate the RB pro-
tein that functions to suppress the activity of E2F-1,
which in turn is required to stimulate the transcription
of genes required for DNA synthesis. Current evidence
supports a model whereby cumulative phosphorylation
of RB displaces bound histone deacetylase (HDAC)
and E2F-1, relieving transcriptional repression and
permitting gene transcription from E2F-1-dependent
promoters (Zhang et al., 2000).
Targeting of CDK2/cyclin E activity by RNA inter-
ference or by small molecules is effective against
human breast cancer cell lines exhibiting CCNE1
amplification (Natrajan et al., 2012). CDKs are not
only involved in orchestrating the correct passage
through the cell cycle, but also key mediators of tran-
scriptional control, in part by the regulation of RNA
polymerase II (Bregman et al., 2000). CDK7/cyclin H
and CDK9/cyclin T phosphorylate RNA polymerase
II on its C-terminal, which is permissive for initiation
and elongation of nascent mRNA transcripts. Interest-
ingly, a number of transcripts involved in cell cycle
control and apoptosis are highly responsive to alter-
ations in transcriptional regulation, the mRNAs hav-
ing short half-lives, and are thus rapidly lost following
inhibition of transcription (Lam et al., 2001). Hence,
some CDK inhibitors are capable of suppressing the
transcription of key genes such as MCL1, MYC,
CCNB2 (cyclin B2), and several IAP family members
(BIRC1, BIRC2, and BIRC3). Therefore, CDK inhibi-
tors have the potential to perturb cell cycle progression
through direct catalytic inhibition of CDK/cyclin
complexes, loss of expression of the partner cyclins,
and also sensitize cells to proapoptotic stimuli.
While it has been reported that CDKs can be dis-
pensable for survival or cell cycle progression, it
appears that this is due to a high degree of redundancy
among the CDKs and their partner cyclins. For exam-
ple, CDK2 knockout in mice proved to be nonlethal
and RNAi-mediated suppression of CDK2 did not
affect cell proliferation (Ortega et al., 2003; Tetsu and
McCormick, 2003). However, CDK1 is essential for
survival in mice (Diril et al., 2012) and dual suppres-
sion of CDK1 and CDK2 presumably overcomes any
redundancy in CDK2 function, resulting in cell cycle
arrest and/or apoptosis (L’Italien et al., 2006). Combi-
natorial targeting of multiple CDKs therefore remains
an attractive approach for cancer therapy (Whittaker
et al., 2017).
We embarked upon a drug discovery program to
develop CDK2 and 9 inhibitors that exhibited signifi-
cantly improved pharmacological properties compared
with the parental clinical drug seliciclib (CYC202,
R-roscovitine) (McClue et al., 2002; Raynaud et al.,
2005; Whittaker et al., 2004). To this end, we identi-
fied CCT068127, a novel trisubstituted purine with
improved potency, selectivity, metabolic stability, and
antitumor activity compared with seliciclib (Wilson
et al., 2011). Here, we describe the biochemical and
cellular characterization of CCT068127 and identify
synergistic drug combinations to further improve the
efficacy of such CDK2/9 inhibitors for the treatment
of colorectal cancer.
2. Materials and methods
2.1. Cell culture and reagents
All human cancer cell lines (HT29, colorectal adeno-
carcinoma; HCT116, colon carcinoma; COLO205,
colon adenocarcinoma; RKO, colon carcinoma;
SKMEL28, malignant melanoma; WM266.4, malig-
nant melanoma) were obtained from the American
Type Culture Collection and grown in the recom-
mended culture medium, supplemented with 10%
FBS, at 37 °C and an atmosphere of 5% CO2. Cell
lines were passaged for less than 6 months upon
receipt. CCT068127 was synthesized as described
(Wilson et al., 2011) and solubilized in dimethyl sul-
foxide to a stock concentration of 10 mmolL1.
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The BCL2 family inhibitor ABT263 was purchased
from Selleck Chemicals (Tse et al., 2008). The ERK
inhibitor VTX-11e was purchased from Tocris
(Aronov et al., 2009).
2.2. In vitro biochemical kinase assays
Profiling of CCT068127 against a panel of ~ 30 recom-
binant human kinases was performed as previously
described (McIntyre et al., 2010; Wang et al., 2004;
Wilson et al., 2011).
2.3. Enzyme expression and purification
The gene encoding full-length human CDK2 was
cloned into the pGEX-6P-1 and transformed into
BL21(DE3)pLysS cells (Promega, Southampton, UK).
Cultures were grown for 2–3 h at 37 °C, and then, the
temperature was decreased to 18 °C prior to induction
with 0.25 mmolL1 IPTG at OD600 = 0.6. The cul-
tures were allowed to grow for an additional 20–24 h
at 18 °C and were harvested by centrifugation. All
purification steps were performed by FPLC at 4 °C.
Harvested cells were resuspended in 50 mmolL1
HEPES buffer (pH 7.5) containing 150 mmolL1
NaCl, 2 mmolL1 DTT, and 0.5 mgmL1 lysozyme
at 4 °C for 1 h. After sonication and centrifugation
(1 h at 29 000 g), the supernatant was purified by
immobilized glutathione Sepharose chromatography
(GE LifeSciences, Little Chalfont, UK). Following
incubation of peak fractions with 3C protease (20 : 1)
at 4 °C, the cleaved GST-tag was separated by size
exclusion chromatography using a Superdex 75 (26/60)
column and eluted with 50 mmolL1 HEPES buffer
(pH 7.4) containing 150 mmolL1 NaCl and
1 mmolL1 DTT. Purified CDK2 was buffer-
exchanged into 100 mmolL1 Na/K phosphate buffer
(pH 7.4) containing 1 mmolL1 DTT and concen-
trated to 10 mgmL1 for crystallization.
2.4. X-ray crystallography
Crystallization was performed at 20 °C using the sitting
drop vapor diffusion method. Crystals of human
CDK2 were grown from 0.1 M HEPES pH 7.5 and
10% PEG3350 over a reservoir of 50 mmolL1
HEPES pH7.5 and 50 mmolL1 Na/K phosphate buf-
fer (pH 7.4). Crystals were harvested in cryoprotectant
containing 1 mmolL1 CCT068127 (50 mmolL1
HEPES pH 7.5, 50 mmolL1 Na/K phosphate buffer
(pH 7.4), 15% PEG3350, 25% (v/v) ethylene glycol,
1% DMSO, and 1 mmolL1 CCT068127) 24 h prior
to data collection. X-ray diffraction data were recorded
at Diamond Light Source (Harwell, Oxfordshire, UK).
Data processing was carried out using XDS, POINT-
LESS/AIMLESS (Evans, 2011), and other programs of
the CCP4i suite (Collaborative Computational Project,
1994) run through the CCP4i2 GUI. The structure was
solved by molecular replacement using PHASER
(McCoy et al., 2007) and pdb 3QXP as a starting
model. REFMAC (Murshudov et al., 1997) was
employed for refinement, and model building was per-
formed using COOT (Emsley et al., 2010). Figures were
prepared using PYMOL (Schr€odinger, LLC, Cam-
bridge, UK). The coordinates of the CDK2-
CCT068127 crystal structure have been deposited in the
Protein Data Bank with accession code 5MHQ.
2.5. Cell proliferation
The effect of CCT068127 and seliciclib on cancer
cell proliferation was measured using the sulforho-
damine B (SRB) assay as described previously
(Whittaker et al., 2004). For long-term colony for-
mation assays, HT29 colon cancer cells were seeded
into 12-well plates and then treated with the inhibi-
tors for 5 days. Compounds were then washed away
and the cells were allowed to proliferate for a fur-
ther 7 days. After this, cells were fixed with 4%
formaldehyde for 30 min, and cellular protein and
DNA were stained with 0.5% crystal violet solution
for 30 min and washed in water to remove excess
dye. The colony plates were imaged on a FluorChem
E System (ProteinSimple, Oxford, UK). Bound dye
was subsequently resolubilized in 10% acetic acid
and absorbance measured at 595 nm to quantify cell
number.
2.6. Western blotting
Cells were seeded at a density of approximately
4 9 105 cells/well in 6-well plates and incubated over-
night prior to drug treatment. They were then har-
vested in NP-40 buffer as previously described
(Whittaker et al., 2004) and lysates were normalized
using the Bradford assay (Bio-Rad, Watford, UK).
Equal amounts of protein were resolved by SDS/
PAGE using 4–12% bis-tris gels (or 6% tris-glycine
gels to demonstrate a mobility shift in RB in
Fig. 3D) and transferred to nitrocellulose membranes
(Life Technologies, Paisley, UK). The antibodies used
in this study are described in Table S1. Primary anti-
bodies were labeled with fluorescently labeled IRDye
secondary antibodies (Li-Cor, Cambridge, UK), and
proteins were visualized using an Odyssey scanner
(Li-Cor).
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2.7. Cell cycle effects
Cell cycle analysis was performed as previously
described (Whittaker et al., 2004). Briefly, for cell cycle
distribution profiles, cells were exposed to inhibitors
for the indicated times, and then attached cells were
harvested by trypsinization. Cells were washed in PBS
and fixed in ice-cold 70% ethanol. Cellular DNA was
stained using propidium iodide and analyzed by flow
cytometry. To determine the number of cells undergo-
ing DNA synthesis, cells were pulsed with 10 lmolL1
bromodeoxyuridine (BrdU, Sigma, Gillingham, UK)
for 30 minutes prior to harvesting. Cells were fixed in
70% ethanol and nuclei were isolated using 2 molL1
HCl and 0.2 mgmL1 pepsin. Incorporated BrdU was
detected using an anti-BrdU antibody coupled to
FITC (Molecular Probes, Paisley, UK), and cells were
quantified by flow cytometry.
2.8. Gene expression analysis
Cells were exposed to the inhibitors for 24 h prior to
RNA extraction with Trizol (Invitrogen, Paisley, UK)
and subsequent mRNA purification by Oligotex (Qia-
gen, Manchester, UK). Eight microgram of mRNA
was labeled with either Cy3 or Cy5 dCTP via RT-
PCR and the labeled probe was then purified and 2 lg
of each sample was hybridized to a custom cDNA
array of 5808 genes spotted onto poly-lysine-coated
glass slides at 65 °C overnight. Slides were scanned
using a GenePix 4000B (Axon Labs, Union City, CA,
USA) and spots verified using GENEPIX software. Data
analysis was performed in GeneSpring (Silicon Genet-
ics, Redwood City, CA, USA). Gene expression data
were analyzed relative to the DMSO controls by com-
parative marker selection using a t-test to rank expres-
sion changes in Gene-E (http://www.broadinstitute.
org/cancer/software/GENE-E/). A ≥ twofold change in
expression was used to refine the selection criteria.
Gene expression profiles were analyzed using Connec-
tivity Map (Lamb et al., 2006) and STRING data-
bases (Franceschini et al., 2013).
For RT-qPCR assays, mRNA was isolated from
cancer cells using RNeasy Mini kit (Qiagen) according
to the manufacturer’s recommendations. Extracted
RNA was used to generate cDNA with the High
Capacity cDNA Reverse Transcription kit (Applied
Biosystems, Paisley, UK). Primer combinations for the
respective genes were designed according to the Har-
vard Primer Bank (http://pga.mgh.harvard.edu/prime
rbank) and are listed in Table S2. Gene expression
was analyzed using Power SYBR Green gene expres-
sion assays (Life Technologies). Quantitative PCR was
carried out in triplicate on the ViiA 7 Real-Time PCR
System (Applied Biosystems).
2.9. siRNA transfection
HT29 cells were reverse-transfected in 6-well or 96-well
plates using 0.4% RNAiMAX (Life Technologies) trans-
fection reagent and 25 nM of ON-TARGETplus siRNA
(Dharmacon, Cambridge, UK) in OptiMem. Cells were
then cultured for 4 days and analyzed as required. A non-
targeting siRNA (siCTRL) and four different siRNAs tar-
geting CDK5 were used (siCTRL: D-001810-01-05;
siCDK5: J-003239-9, J-003239-10, J-003239-11, J-003239-
12).
2.10. Statistical analysis
For statistical analysis of protein expression data, the
mean of three independent repeats per condition was
used for two-tailed t-tests to determine significance of
change, relative to the appropriate control. This was
deemed the most appropriate test as nonparametric
tests such as the Mann–Whitney U-test require greater
sample numbers to enable significance testing, as dis-
cussed by Krzywinski and Altman (2014).
3. Results
3.1. CCT068127 is a potent and stable inhibitor of
CDK2 and 9
We previously reported a medicinal chemistry cam-
paign to generate more potent, selective, and metaboli-
cally stable analogs of the clinical cyclin-dependent
kinase inhibitor seliciclib (CYC202, R-roscovitine)
(Wilson et al., 2011). CCT068127 was identified as
having significantly increased potency toward human
CDK1/cyclin B (15-fold), CDK2/cyclin E (22-fold),
CDK5 (15-fold), and CDK9/cyclin T (11-fold) kinase
activities, when compared to the parental seliciclib
(Table 1). Importantly, selectivity toward CDK2 and 9
versus CDK4 and CDK7 is enhanced compared to
seliciclib, as the concentration required to inhibit
kinase activity by 50% (IC50) remained relatively
unchanged for CDK4/cyclin D and CDK7/cyclin H.
Although the potency of CCT068127 for CDK1 is
increased over seliciclib, the IC50 is still relatively high
at 1.12 lM. Overall, CCT068127 showed greatest
in vitro potency against CDK2, CDK5, and CDK9.
CCT068127 displays notably improved cellular
activity compared with seliciclib, with the average con-
centration to reduce cell proliferation by 50% (GI50)
in a panel of human colon cancer and melanoma cell
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lines being 0.5 lmolL1 versus 12 lmolL1, respec-
tively. This 20-fold increase in cellular potency was
consistent with the enhanced activity against CDK2,
CDK5, and CDK9 (Table 2). In addition, we have
previously reported that CCT068127 displays greater
metabolic stability than seliciclib (Wilson et al., 2011).
3.2. Crystal structure of CCT068127 bound to
CDK2
Based on structure–activity relationships for synthe-
sized analogs (Wilson et al., 2011), we hypothesized
that the more potent inhibition of CDK2 and CDK9
for CCT068127 in comparison with seliciclib (Table 1)
is due to the presence of the pyridyl nitrogen and the
methyl group of defined stereochemistry in the hydrox-
yalkyl side chain of CCT068127 (Fig. 1A). Our initial
in silico docking suggested that, compared to seliciclib,
the hydroxyl group of CCT068127 could form an
additional hydrogen bond with Asp145 of the DFG
motif in human CDK2 (data not shown).
To determine the precise binding mode, we deter-
mined the X-ray crystal structure of CCT068127 with
CDK2 (Fig. 1B). The CCT068127–CDK2 complex
formed crystals with space group P212121 that dif-
fracted to 1.3A resolution. The structure was refined
to Rfactor and Rfree values of 19.6% and 23.4%,
respectively (Table S3). This shows that CCT068127
acts as a type I kinase inhibitor of CDK2 and binds to
the hinge region of the ATP binding pocket through
two hydrogen bonds, formed by the purine N7 and
the exocyclic nitrogen at C6 of the purine scaffold that
interact with the main chain amine and carbonyl of
Leu83, respectively (Fig. 1B,C). In addition, our high-
resolution electron density map of the inhibitor–CDK2
complex has allowed unambiguous assignment of the
conformation of the hydroxymethyl moiety. As pre-
dicted by our modeling, the side chain hydroxyl forms
an additional hydrogen bond with the carboxylic acid
side chain of Asp145, part of the DFG motif. Electron
density indicates two alternate conformations for the
hydroxyl group, with the minor pose forming an inter-
action with the main chain carbonyl of Gln131. Also
CCT068127 forms multiple van der Waals (hydropho-
bic) interactions with surrounding residues
(3.4A < d < 4.0A). The purine core is sandwiched
between Ile10 and Leu134, with the N9-isopropyl moi-
ety stacking up against the gatekeeper residue Phe80.
Superimposition of CDK2 structures bound to
CCT068127 and seliciclib illustrates a key rotation of
the C2 substituent that orients the pendant hydroxyl
moiety toward Asp145. The additional hydrogen
bound formed in this altered pose provides a plausible
explanation for the increased potency CCT068127 rela-
tive to seliciclib (Fig. 1D). The pyridine moiety of
CCT068127 is slightly shifted relative to the phenyl
group of seliciclib (Fig. 1D) possibly resulting from
the engagement of the pyridine nitrogen in water-
mediated hydrogen bonds with CDK2.
Table 1. In vitro kinase inhibition by CCT068127 and seliciclib.
Compounds were tested against human recombinant enzymes
in vitro as previously described (McIntyre et al., 2010; Wang et al.,
2004; Wilson et al., 2011) except for CDK5/p35, which was carried
out using the Invitrogen Select Screen service. Results are the
mean of three independent repeats  SE except for CDK5/p35,
which is the mean of two determinations. The following kinases
had IC50 values greater than 10 lmolL1 for both compounds:
ABL, AKT, CAMKII, CK2, ERK2, GSK3, PKA, PKC, PLK1, S6,
SAP2KA, AURKA, FLT3, SRC, LCK, PDGFB, AURKB, VEGFR1,
VEGFR2, and IKKA. Data for seliciclib were reported previously
(Mariaule and Belmont, 2014; Wilson et al., 2011).
Kinase assay
CCT068127
Mean IC50 (lmolL1)  SE
Seliciclib
IC50 (lmolL1)
CDK1/B 1.1  0.29 17
CDK2/A 0.11  0.02 ND
CDK2/E 0.010  0.001 0.22
CDK4/D1 4.8  0.6 27
CDK5/p35 0.07 1.0
CDK6/D3 6.2  0.6 ND
CDK7/H 0.52  0.09 0.52
CDK9/T 0.09  0.03 0.80
Table 2. Antiproliferative activity of CCT068127 and seliciclib in
human colon cancer and melanoma cell lines. GI50 values for cell
proliferation were determined in human colon cancer and
melanoma cell lines following exposure for four population
doublings using SRB analysis as the endpoint (Whittaker et al.,
2004). Values reported are the mean of three independent
repeats  SE. ND, not determined.
Cell line Tissue
CCT068127
GI50 (lmolL1)
 SE
Seliciclib
GI50 (lmolL1)
 SE
HT29 Colorectal
adenocarcinoma
0.85  0.03 15  3.4
HCT116 Colon carcinoma 0.25  0.03 6.4  1.8
COLO205 Colon
adenocarcinoma
0.50  0.09 11  1.2
RKO Colon carcinoma 0.66  0.03 10  0.26
SKMEL28 Malignant
melanoma
0.31  0.07 8.5  2.1
WM266.4 Malignant
melanoma
0.40  0.06 18  2.4
Average – 0.5 12
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A 
B 
C D 
Fig. 1. Enhanced potency of CCT068127 over seliciclib is achieved by additional ligand interactions with CDK2 and CDK9. (A) Chemical
structures of seliciclib and CCT068127; numbering of the purine scaffold is indicated for CCT068127. (B) Secondary structure representation
of human CDK2 in complex with CCT068127 determined by X-ray crystallography at 1.3 A resolution. The inset shows the binding
interactions of CCT068127 within the ATP binding pocket. The hinge region is indicated in orange, Asp145 of the DFG motif in cyan, and
CCT068127 in yellow. Displayed in blue is the 2Fo-Fc electron density, contoured at 1r around CCT068127. The data and refinement
statistics are shown in the Supporting information (Table S3). The hydrogen bonding and van der Waals (hydrophobic) interactions are
shown as black and green dotted lines, respectively. PDB: 5MHQ. (C) Schematic presentation of the binding interactions between
CCT068127 and CDK2. (D) Alignment of CCT068127 (yellow) and seliciclib (magenta) (PDB: 3DDQ) bound to CDK2.
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3.3. Inhibition of CDK2 and CDK9 activity
correlates with decreased substrate
phosphorylation in cells
To confirm that CCT068127 retains activity against
CDKs in cells, the phosphorylation of selected CDK
substrates was determined. We used a cell-based assay
for protein phosphatase 1 phosphorylation to measure
CDK1 activity following compound treatment. PP1
phosphorylation at T320 shows inhibition with an
IC50 of 6 lM for CCT068127 and 71 lM for seliciclib,
4–9 times greater than the respective GI50 values
(Fig. S1) (Kwon et al., 1997). Of note, cyclin B1
expression was reduced only at higher concentrations,
with an IC50 of 15 lM for CCT068127 and >100 lM
for seliciclib, suggesting that loss of cyclin B1 con-
tributes to, but is not primarily responsible for, the
antiproliferative activity of these compounds. Phos-
phorylation of the RB protein by CDKs facilitates
DNA synthesis and cell cycle progression through the
displacement of HDACs and E2F family transcription
factors from RB (Brehm et al., 1998). The phosphory-
lation status of RB was therefore assessed following a
24-h exposure to CCT068127 or seliciclib in HT29,
RKO, and COLO205 human colon cancer cells
(Figs 2A and S2A). We found that a concentration of
3 lmolL1 CCT068127 or greater reduces phosphory-
lation of RB at S780, whereas 30 lmolL1 seliciclib is
required to elicit the same effect, consistent with at
least a 10-fold greater potency of CCT068127 over
seliciclib in the biochemical assays with recombinant
proteins. Notably, the inhibition of RB phosphoryla-
tion was only partial (~50%) as determined by quan-
tification of the blots and was less pronounced in the
COLO205 cells, due to the loss of total protein
(Figs 2B and S2B).
In addition to effects on the cell cycle mediated
through inhibition of RB phosphorylation, CDKs
are known to regulate transcription through modifi-
cation of RNA polymerase II, which is required for
the generation of some transcripts arising from pol
II-dependent promoters (Oelgeschlager, 2002). Phos-
phorylation of RNA polymerase II at S5 and S2 is
catalyzed by CDK7 and CDK9, respectively,
although other CDKs have also been shown to tar-
get these sites (Jeronimo et al., 2016). Inhibition of
these CDKs by compounds such as flavopiridol and
seliciclib has been shown to have dramatic effects on
the transcriptional machinery leading to a profound
inhibition of transcription (Lam et al., 2001; Whit-
taker et al., 2004, 2007). RNA polymerase II phos-
phorylation was assessed at S2 following treatment
with CCT068127 or seliciclib (Figs 2A and S2A). We
found that inhibition of RNA polymerase II phos-
phorylation occurs following treatment with
3 lmolL1 or greater CCT068127. Seliciclib is less
potent, again requiring approximately 30 lmolL1
to reduce RNA polymerase II phosphorylation to
equivalent levels. This is likely in part due to the
loss of total protein as previously observed (Whit-
taker et al., 2004). In contrast to RB, RNA poly-
merase II S2 phosphorylation was more completely
inhibited (up to 80%) by both compounds (Figs 2B
and S2B). Interestingly, we found that phosphoryla-
tion of S5 of RNA polymerase II was less sensitive
to treatment and reflected loss of the total protein
more than specific loss of phosphorylation (data not
shown).
Time-course experiments using a 3xGI50 concentra-
tion of both compounds were also performed in HT29
and RKO human colon cancer cells. Equiactive con-
centrations of each compound were used to enable a
comparison of the molecular alterations induced by
each compound at concentrations that have similar
effects on cell proliferation/survival. We found that
both compounds inhibit RB phosphorylation with sim-
ilar kinetics from 16 to 24 h (Figs 2C,D and S2C,D).
RNA polymerase II phosphorylation is inhibited more
rapidly, with both compounds reducing phosphoryla-
tion at S2 from 4 to 24 h (Figs 2C,D, and S2C,D). As
expected, the inhibition of RNA polymerase II phos-
phorylation is associated with decreased expression of
the protein at later time points. These data demon-
strate that loss of RNA polymerase II phosphorylation
precedes loss of RB phosphorylation. To evaluate
whether the expression of CDKs was being modulated
by seliciclib and CCT068127, the levels of CDK1, 2, 5,
and 9 were assessed following a 24-h exposure to these
compounds (Fig. S3A). The expression of these pro-
teins was largely unaltered, with the exception of
CDK9, which was decreased at 30–100 lM seliciclib
and 3–10 lM CCT068127 in HT29 cells and at 100 lM
seliciclib and 10 lM CCT068127 in RKO cells. The
expression of cyclins E1, T1, B1, and D1 was also
assessed and cyclin D1 levels were found to be
decreased by CCT068127 and seliciclib (Fig. S3A);
more modest decreases in cyclin T1 were observed with
CCT068127. Notably, cyclin E1 expression was
increased by seliciclib (10–30 lM) and by CCT068127
(0.3–1 lM) (Fig. S3A). This may reflect inhibition of
CDK2, which is known to phosphorylate cyclin E1
and target it for degradation (Clurman et al., 1996),
and has been reported as a marker of CDK2 inhibi-
tion (Sakurikar et al., 2016). We could not detect
expression of the p35 regulatory subunit of CDK5,
which is reportedly expressed primarily in postmitotic
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neurons, although a role in cancer is emerging (Shupp
et al., 2017). To specifically address the effect of
reduced CDK5 activity on cell proliferation, we used
four different siRNAs to deplete HT29 cells of CDK5
by 80–90% (Fig. S4A). Under these conditions, we
observed minor reductions of up to 10–20% in
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proliferation with two of the four siRNAs tested, with
the remaining two siRNAs having no effect despite
good knockdown of CDK5 expression (Fig. S4B). A
time course of seliciclib and CCT068127 showed that
the decrease in CDK9, cyclin T1, and cyclin D1
expression occurred at 16–24 h (Fig. S3B), whereas
inhibition of RNA polymerase II phosphorylation was
observed as early as 4 h (Fig. 2C,D). This is consistent
with direct inhibition of CDK9 mediating the early
effects of these compounds, although at later time
points effects on transcription may also contribute to
the loss of CDK activity, for example, by cyclin
depletion.
3.4. Inhibition of cell cycle progression and DNA
synthesis by CCT068127
To investigate the cell cycle effects of CCT068127,
HT29 colon cancer cells were exposed to the respective
3xGI50 concentrations of seliciclib or CCT068127 for
4, 12, and 24 h and the effect on cell cycle distribution
and DNA synthesis was assessed by incorporation of
PI measured by flow cytometry (Fig. 3A). A modest
reduction in the proportion of cells with 2n DNA con-
tent (~ 10%) and an increase in cells with 4n DNA
content (~ 10%) are seen with both compounds
(Fig. 3B). CCT068127 and seliciclib both blocked
DNA synthesis, as determined by BrdU incorporation,
although CCT068127 achieved this more rapidly than
seliciclib and with 14-fold greater potency (Fig. 3C).
In both cases, the block in DNA synthesis is near
complete at 24 h. Analysis of parallel treatments
demonstrated a loss of RB phosphorylation as demon-
strated by a mobility shift in the protein on SDS/
PAGE (Fig. 3D).
3.5. Gene expression profiling of seliciclib
analogs
In order to explore the potential similarities between
seliciclib and CCT068127 in an unbiased manner, gene
expression profiling was performed on HT29 human
colon cancer cells treated with the respective 3xGI50
concentrations of the inhibitors for 24 h. As a control,
cells were also treated with an inactive analog of selici-
clib, CCT068152, and mRNA expression was mea-
sured. This compound displays no inhibitory activity
against purified CDKs, has a GI50 > 50 lM on HT29
cells, and does not inhibit RB phosphorylation
(Fig. S5). Comparison with this compound would
potentially highlight any off-target effects of the
amino-purine chemical backbone of the series.
CCT068152 was used at an equimolar concentration
when compared with seliciclib. Gene expression was
determined using custom expression arrays (Whittaker
et al., 2007). A table showing the transcriptional
changes induced by each compound is presented in
Table S4. When the gene expression changes induced
by seliciclib and CCT068127 compound are plotted
against each other, they show good concordance
(Fig. 4A).
We found that seliciclib and CCT068127 share a
core set of 198 genes (of a total of 577 affected) that
are either increased or decreased in expression fol-
lowing treatment (Fig. 4B). This is consistent with
the view that CCT068127 retains some of the same
characteristics as seliciclib, although other effects
may contribute. Of these shared 198 genes, the
expression of only 10 is also altered by the inactive
analog CCT068152, suggesting that these are likely
off-target effects, whereas the others are on-target. In
fact, we found that the inactive analog changes the
expression of only 37 genes, markedly fewer than
either seliciclib or CCT068127. For further analysis,
genes that were altered in expression by CCT068152
were excluded.
The mRNA expression changes induced by treat-
ment of HT29 cells with either seliciclib or CCT068127
were used to define a signature for each compound by
identifying genes altered in expression by ≥ twofold
following treatment. We then analyzed these signatures
for similarity to known drug-induced gene expression
Fig. 2. CCT068127 potently inhibits RB and RNA polymerase II phosphorylation in human cancer cells. (A) HT29 and RKO colon cancer cells
were treated with increasing concentrations of CCT068127 or seliciclib for 24 h. Cell lysates were analyzed by western blotting for the
phosphorylation of RB (a measure of CDK2 inhibition) and phosphorylation of RNA polymerase II (a measure of CDK9 inhibition). (B)
Quantification of RB S780 and RNAPII S2 phosphorylation in (A), normalized to total RB or total RNAPII, respectively, and expressed as a
percentage of the DMSO control (mean percentage of control values presented from three independent repeats  SE, significant difference
from control indicated by *P < 0.05, **P < 0.01, ***P < 0.001, two-tailed t-test). (C) HT29 and RKO cells were treated with equiactive
(3xGI50, SRB assay) concentrations of CCT068127 (2.55 lM for HT29 and 1.98 lM for RKO) or seliciclib (45 lM for HT29 and 30 lM for RKO)
for the indicated times. A: asynchronously growing, untreated cells; D24: cells treated with DMSO for 24 h. Cell lysates were analyzed by
western blotting for the indicated proteins. (D) Quantification of RB S780 and RNAPII S2 phosphorylation in (C), normalized to total RB or
total RNAPII, respectively, and expressed as a percentage of the time 0 control (mean percentage of control values presented from three
independent repeats  SE, significant difference from control indicated by *P < 0.05, **P < 0.01, ***P < 0.001, two-tailed t-test).
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changes using the Connectivity Map (Lamb et al.,
2006). Strikingly, signatures for both compounds show
a high level of correlation with those of other small-
molecule CDK inhibitors, namely 0175029-0000 (Khan
et al., 2012), alsterpaullone (Schultz et al., 1999), and
GW8510 (Bramson et al., 2001), as well as HDAC
inhibitors vorinostat/SAHA (Richon et al., 1998),
trichostatin A (Yoshida et al., 1990), valproic acid
(Gottlicher et al., 2001) (Tables S5 and S6).
We also utilized the STRING database (Frances-
chini et al., 2013) to look for functional associations
between genes with altered expression in response to
CDK inhibition (Fig. S6). A cluster of genes involved
in G2/M cell cycle progression is immediately evident,
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Fig. 3. Induction of cell cycle arrest by CCT068127 and seliciclib. (A) HT29 human colon cancer cells were incubated with equiactive
(3xGI50, SRB assay) concentrations of CCT068127 or seliciclib for 4-24 h. Cell cycle distribution was assessed by propidium iodide staining
and analysis by flow cytometry. (B) Quantification of cell cycle distribution profiles from (A). Data presented are the mean of three
independent experiments  SE. (C) HT29 cells were treated as in (A) and were pulse-labeled with BrdU, then fixed, and stained with
propidium iodide. BrdU incorporation was determined using a FITC-conjugated antibody to BrdU and detected by flow cytometry. The
percentage of BrdU positive cells is indicated. (D) HT29 cells were treated as in (A) and cell lysates were analyzed by western blotting for
the indicated proteins. The arrow indicates hypophosphorylated RB.
Fig. 4. Gene expression analysis of colon cancer cells following treatment with CCT068127 and seliciclib. (A) HT29 cells were treated with
equiactive concentrations (3xGI50, SRB assay) of seliciclib (45 lM) and CCT068127 (2.55 lM) or 45 lM CCT068152. mRNA expression
profiles were generated using a custom microarray enriched for 5808 cDNAs implicated in cancer. Genes that were differentially expressed
between the CDK inhibitor- and the DMSO-treated cells were determined using comparative marker selection (t-test) and a ≥ twofold
change in expression as a filter. The mRNA expression changes for seliciclib and CCT068127 were plotted against each other. (B) Venn
diagram was constructed to show the number of genes in common between the two CDK inhibitors, and the inactive analog CCT068152,
which displayed either increased or decreased expression following treatment. (C) mRNA expression changes following treatment of HT29,
COLO205, or RKO human colon cancer cells with 3xGI50 concentrations of CCT068127 or seliciclib for 4 and 24 h as determined by RT-
qPCR. (D) HT29 cells were treated with 5xGI50 concentrations of CCT068127 (4.25 lM) or seliciclib (75 lM) for 15, 30, 60, or 120 minutes
and cell lysates analyzed for the indicated proteins by western blotting. (E) HT29 cells were treated with a range of concentrations of
CCT068127 or seliciclib for 24 h. Cells were lysed and extracts were analyzed by western blotting for the proteins listed. (F) HT29,
COLO205, and RKO cells were treated with either DMSO or 3xGI50 concentrations of CCT068127 or seliciclib for 4, 24, and 48 h and
protein lysates analyzed by western blotting for the indicated proteins. Data are representative of three independent repeats. (G) The
expression of MCL1 in (F) was quantified and normalized to vinculin expression. Data are the mean of three independent repeats  SE. (H)
Cells were treated as in (F) and the expression of MCL1 mRNA was quantified by qRT-PCR, normalized to the housekeeping gene GUSB.
The mean  SE of triplicate measurements is presented.
296 Molecular Oncology 12 (2018) 287–304 ª 2017 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
A novel inhibitor of CDK2 and CDK9 S. R. Whittaker et al.
F G 
A B 
D E 
C 
H 
297Molecular Oncology 12 (2018) 287–304 ª 2017 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
S. R. Whittaker et al. A novel inhibitor of CDK2 and CDK9
including decreased expression of several mitosis-
related genes, including PLK1, CCNB2, AURKA,
AURKB, CDC25B, UBE2C, and CENPF (Fig. S6).
These changes could bring about a G2/M-phase arrest,
which would be consistent with the 4n DNA popula-
tion reflecting an increased G2/M phase and the
reduced transcriptional output induced by the CDK
inhibitors as we have previously characterized for seli-
ciclib (Whittaker et al., 2007). We confirmed these
gene expression changes by RT-qPCR (Fig. 4C). Alter-
natively, this could also reflect a population of
G1-phase cells with 4n DNA content, which may arise
through mitotic slippage, due to premature loss of
CDK1/cyclin B activity (Rieder and Maiato, 2004).
As part of the overall core transcriptional profile
determined by microarray (see above), we identified
transcription factors downstream of the MAPK path-
way whose expression is increased in response to the
CDK inhibitors; these changes were also confirmed by
RT-qPCR (Fig. 4C). For example, the expression of
the transcription factor-encoding genes EGR1 (coding
for early growth response protein 1) and IER2 (encod-
ing immediate early response 2) was induced (Boros
et al., 2009; Hodge et al., 1998). In contrast, the
expression of DUSP6—encoding dual-specificity phos-
phatase 6 that acts as a negative regulator of ERK2
by decreasing phosphorylation (Muda et al., 1996)—is
reduced. Consistent with this, we have previously
observed phosphorylation/activation of extracellular
signal-regulated kinases (ERKs) in response to selici-
clib in human colon cancer cell lines (Whittaker et al.,
2004). Our observation here of increased expression
of transcripts regulated by the MAPK pathway was of
particular interest as this suggested that activation of
the pathway has functional consequences. We con-
firmed that treatment of HT29 cells with CCT068127
or seliciclib for 15, 30, 60, and 120 minutes results in
rapid phosphorylation of ERK1/2 and that this is seen
in the absence of any dramatic changes in the phos-
phorylation state of the upstream kinases MEK1 and
MEK2 (Fig. 4D). Therefore, we determined the
expression at the protein level of the ERK2-phospha-
tase DUSP6, which as noted above shows reduced
mRNA expression. We found that DUSP6 protein
levels reduce rapidly, within 1–2 h following treatment
with either CCT068127 or seliciclib, commensurate
with increased ERK1/2 phosphorylation (Fig. 4D).
We also noted that CDK inhibitor treatment alters
transcription of the antiapoptotic gene MCL1, which
belongs to the BCL2 family. Although we observed an
increase in MCL1 mRNA at 24 h by microarray, RT-
qPCR analysis showed an initial decrease at 4 h, fol-
lowed by a rebound to untreated levels or higher by
24 h (Fig. 4C). We found that MCL1 protein expres-
sion is decreased by both CCT068127 and seliciclib
within 2 h of treatment (Fig. 4D) (Whittaker et al.,
2007). Interestingly, unlike the mRNA, expression of
MCL1 protein does not recover for 24 h with either
seliciclib or CCT068127 (Fig. 4E). Sustained suppres-
sion of MCL1 protein expression by seliciclib and
CCT068127 was confirmed in HT29 and COLO205
cells out to 48 h, whereas in RKO cells MCL1 protein
was decreased at 4 h but recovered to near-control
levels at 24 and 48 h (Fig. 4F–H). qRT-PCR of all of
these cell lines treated as in Fig. 4F demonstrated that
mRNA levels for MCL1 showed modest decreases at
4 h of treatment, followed by recovery to control
levels or greater at 24 and 48 h. Notably, loss of
MCL1 protein occurs at the same concentrations at
which we also observe PARP cleavage—a marker of
caspase activation and apoptosis (Fig. 4E). Hence, loss
of MCL1 protein might present a deficit in the balance
of antiapoptotic versus proapoptotic signals, resulting
in the induction of apoptosis.
3.6. Combined inhibition of CDKs and the BCL2
family is synergistic
Our observation that CCT068127 treatment gives rise
to enhanced MAPK signaling prompted us to hypoth-
esize that activation of the MAPK pathway might pro-
vide a survival signal to the cells. We therefore treated
HT29 human colon cancer cells with a selective inhibi-
tor of ERK known as VTX-11e (Aronov et al., 2009)
in combination with CCT068127; we then determined
the effect on cell proliferation and survival after 4 days
and calculated synergy using a well-established method
(Chou and Talalay, 1984). Under these conditions, the
ERK inhibitor plus CCT068127 gave combination
index (CI) values of >1 and was classified as antago-
nistic (Fig. 5A).
As we also observed a loss of the antiapoptotic
MCL1 protein in response to CDK inhibitor treat-
ment, we posited that this depletion of MCL1 might
create a dependency upon other antiapoptotic pro-
teins, such as additional members of the BCL2 fam-
ily, and that a BCL2 family inhibitor might be
synergistic with CCT068127. Hence, we investigated
the response of HT29 cells to a 96-h exposure to
the combination of CCT068127 and ABT263, an
inhibitor of BCL2 family proteins (Tse et al., 2008).
Excitingly, we observed with a CI value ~0.5 or
lower, indicating a synergistic antiproliferative effect
with the combination of these two agents (Fig. 5B).
We confirmed that the combination of these two
agents results in an increased antiproliferative/
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cytotoxic effect as measured by colony formation
assay in HT29, COLO205, and RKO cells (Fig. 5C).
Colorectal cancer cells were exposed to 1 lM
CCT068127, 750 nM ABT263, or a combination of
both drugs for a period of 5 days. The drugs were
then washed out and the cells grown in medium
only for a further 7 days. We observed that the
combination of CCT068127 and ABT263 results in a
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Fig. 5. Targeting CDK2/9 and BCL2 family members synergistically inhibits proliferation and induces apoptosis. (A) HT29 human colon
cancer cells were treated with increasing concentrations of CCT068127 in combination with a small-molecule inhibitor of ERK, VTX-11e.
Cells were treated with both compounds in a 1.5-fold dilution series starting at 5X the GI50 (4.25 lM CCT068127 and 243 nM VTX-11e) in a
1 : 1 ratio. Cell proliferation/survival was assessed by SRB assay, and synergy was calculated using the combination index (CI) methodology
(Chou and Talalay, 1984). Data from four independent repeats were analyzed by CALCUSYN software, and the mean CI  SE is plotted relative
to the fraction of cells affected by the treatment. Values < 1 are indicative of synergy. (B) HT29 cells were treated as in (A) except the ERK
inhibitor was replaced by the BCL2 family inhibitor ABT263. Cells were treated with both compounds in a 1.5-fold dilution series starting at
5X the GI50 (4.25 lM CCT068127 and 12.7 lM ABT263) in a 1 : 1 ratio. The mean combination index  SE is plotted relative to the fraction
of cells affected by the treatment. Values < 1 are indicative of synergy. (C) HT29, COLO205, and RKO human colon cancer cells were
treated with 1 lM CCT068127 or 750 nM ABT263 alone, or in combination for 5 days after which the medium was replaced and cells were
cultured in medium alone for a further 7 days. Cells were then fixed and stained with crystal violet. Data shown are representative of three
independent experiments. (D) HT29, COLO205, and RKO cells were treated with 1 lM CCT068127 in the presence and absence of 750 nM
ABT263 for 48 h. Cell lysates were analyzed by western blotting for the indicated proteins.
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significantly greater suppression of measurable cell
colony formation than when used as single agents
(Fig. S7). Furthermore, exposure of HT29,
COLO205, and RKO human colon cancer cells to
both compounds in combination for 48 h results in
a greater degree of PARP cleavage, indicative of
apoptotic cell death (Fig. 5D).
4. Discussion
We set out to discover a CDK2/9 inhibitor with
greater potency and metabolic stability compared with
the parent compound seliciclib (Wilson et al., 2011).
CCT068127 exhibits 15-fold greater potency against
CDK1/cyclin B, 14-fold greater potency against
CDK5/p35, 22-fold greater potency against CDK2/cy-
clin E, and 11-fold greater potency against CDK9/cy-
clin T. In contrast, potency toward CDK4 and CDK6
increased only by 6- to 8-fold and that for CDK7/cy-
clin H potency remained the same; therefore, selectiv-
ity for CDK2 and 9 was increased over CDKs 4, 6,
and 7. Despite increased potency against CDK1, a
cell-based assay for PP1 phosphorylation at T320
demonstrated that CDK1 was not inhibited at concen-
trations of CCT068127 (or seliciclib) where cellular
effects on proliferation and signaling occurred. The
basis for greater potency against CDK2 was suggested
by the crystal structure of CCT068127 bound to
CDK2, whereby the pendant C2 side chain hydroxyl
moiety forms an additional hydrogen bond with
Asp145 of the DFG motif. Improved enzyme potency
translated into greater antiproliferative activity against
human cancer cell lines with an average GI50 24-fold
lower than that observed with seliciclib. Importantly,
there was a clear correlation between the suppression
of key pharmacodynamic markers for CDK2 and
CDK9 (phosphorylation of RB and RNA polymerase
II, respectively) and the inhibition of cell proliferation.
Notably, RNA polymerase II was inhibited more
rapidly and near completely compared to RB by both
seliciclib and CCT068127, suggesting that inhibition of
CDKs targeting RNA polymerase II may be a primary
driver of the cellular response to these agents. This is
consistent with a recent study in which seliciclib was
shown to bind to CDK7, 12, 9, and 2 in an affinity
pull-down assay (Delehouze et al., 2014). The conse-
quence of CDK9 inhibition appears to be a gradual
reduction in the expression of cyclin D1, cyclin T1,
and CDK9 itself presumably via inhibition of tran-
scriptional elongation by RNA polymerase II. Thus,
these agents may primarily target CDKs that regulate
transcription but, through cyclin or CDK depletion,
result in inhibition of additional cell cycle CDKs as
well. While in vitro biochemical data suggest that
CCT068127 showed greatest potency for CDK2,
CDK5, and CDK9, our cellular studies suggest that
CDK9 may be a key target of this compound, sup-
ported by the key observations of the greater magni-
tude of inhibition of RNA polymerase II
phosphorylation over RB, that the catalytic subunit of
CDK5 was not detectable in the HT29 and RKO cell
lines, and that siRNA-mediated reduction in CDK5
expression did not have marked effects on HT29 cell
proliferation. However, we cannot rule out the possi-
bility that inhibition of these, and potentially other
CDKs, may contribute to the mechanism of action of
these compounds or additional effects in vivo.
In terms of cell cycle effects, CCT068127 caused the
same arrest of cell cycle progression as seen with selici-
clib, with a reduction in cells with 2n DNA content
and an increase in cells with 4n DNA content, but was
able to achieve this at a concentration 15-fold lower
than that required for seliciclib. Overall, CCT068127
retained the same cellular effects as the developmental
clinical drug seliciclib but with significantly improved
potency and, as we have reported previously, has
improved metabolic stability and displays greater
in vivo efficacy in a tumor xenograft model (Wilson
et al., 2011).
We further investigated the mechanism of action of
CCT068127 by comparing the transcriptional signature
induced by the compound in the HT29 human colon
cancer cell line to the expression signatures available
in the Connectivity Map database. The signatures
most highly correlated with that of CCT068127 are
those for other CDK inhibitors and, in addition,
HDAC inhibitors. The close correlation between these
two compound classes may stem from their ability to
broadly modulate transcription and that functional
RB recruits histone deacetylase to suppress E2F-regu-
lated transcription (Brehm et al., 1998), which is
enhanced by CDK inhibition. More global effects on
transcription are also likely to be a result of decreased
RNA polymerase II activity, through inhibition of
CDKs including CDK9.
It is interesting to note that treatment with
CCT068127 induces rapid activation of ERK1/2 and
we were keen to determine how this was mediated and
whether there was an associated dependency upon
MAPK signaling for survival of the cells. As the phos-
phorylation state and expression of MEK1/2 appeared
to be unaltered by CCT068127 treatment, our results
suggested that upstream activation of the MAPK
pathway was likely not mediating this effect. In fact,
decreased protein expression of the ERK phosphatase
DUSP6 occurs at the same time and concentrations of
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CCT068127 as the observed induction of ERK1/2
phosphorylation. It therefore seems likely that loss of
DUSP6 expression permits increased ERK1/2 phos-
phorylation and activation of the pathway (Muda
et al., 1996). Consistent with this, the mRNAs for
EGR1 and IER2 were induced by both inhibitors, sug-
gesting some capacity of ERK to positively modulate
transcription. Given the positive regulation of cell pro-
liferation and survival mediated by the MAPK path-
way, we hypothesized that addition of an ERK
inhibitor would block any proliferative or survival sig-
naling through MAPK. Surprisingly, this was not the
case and rather than showing synergy with
CCT068127, the ERK inhibitor was antagonistic.
ERK inhibition reportedly induces a G1 arrest (Morris
et al., 2013) and therefore could potentially protect
cells from CDKi-mediated apoptosis, particularly if
driven by deregulation of E2F during S phase (Qin
et al., 1994; Wu and Levine, 1994).
The mRNA expression profiling data showed an
increase in the transcript levels of the antiapoptotic
gene MCL1 in the HT29 cell line. Previously, we had
seen this with seliciclib treatment but the expression
of MCL1 protein was rapidly decreased in response
to CDK inhibition (Whittaker et al., 2007) as has
been described for several other CDK9 inhibitors
(Gregory et al., 2015; Lemke et al., 2014; Ma et al.,
2003). Further RT-qPCR analysis showed that MCL1
mRNA was initially inhibited in all three cancer cell
lines at 4 h but was substantially increased in HT29
and RKO cells by both seliciclib and CCT068127 at
24–48 h. However, MCL1 protein levels were
decreased by both compounds at 4–48 h in HT29 and
COLO205 cells, whereas RKO cells showed a
decrease at 4 h and recovery at 24–48 h. Given the
effect of CDK2 and CDK9 inhibition on the cell
cycle and global transcriptional regulation, presum-
ably sustained MCL1 protein suppression at 24–48 h
is due to either inhibition of translation of the mRNA
or accelerated protein degradation (Choudhary et al.,
2015). Notably, the RKO cells recover expression of
MCL1 protein at 24–48 h so may regulate MCL1
protein expression differently to the HT29 and
COLO205 cells. Irrespective of the precise mechanism,
the loss of MCL1 protein presented a possible thera-
peutic opportunity to further target the antiapoptotic
BCL2 family with a small-molecule inhibitor and
enhance the proapoptotic activity of CCT068127.
Combined use of CCT068127 and ABT263, a BCL2
family inhibitor, led to synergistic antiproliferative
activity and consistent with this, we saw elevated cas-
pase activation indicative of apoptosis and reduced
cell survival in colony formation assays. Excitingly,
this presents a highly rational and mechanistically
defined combinatorial approach to target cancer cell
survival. Given that MCL1 is amplified in approxi-
mately 11% of cancers and overexpression of the pro-
tein is associated with chemoresistance (Beroukhim
et al., 2010), the combination of a CDK2/9 inhibitor
with a BCL2 family inhibitor presents an attractive
therapeutic strategy for those cancers that may have
an increased dependency on MCL1. To our knowl-
edge, this is the first demonstration that combination
of a CDK2/9 inhibitor and a BCL2 family inhibitor
is beneficial in human colorectal cancer cell lines and
may support widening the scope of indications in
which these agents are tested. Overall, our data sup-
port the continued clinical development of this series
of CDK2/9 inhibitors, from which CYC065 has now
entered first-in-human studies (Cyclacel Ltd. press
release October 22, 2015).
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